Sunday 18 October 2026
Export EVAX’s income statement to Excel — free account
Evaxion A/S - Sponsored ADR
EVAX Healthcare Biotechnology
Evaxion A/S - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, up 125.1% from fiscal 2024. In the quarter to June 2026, revenue grew 14,590.2%, EPS fell 72.4% and free cash flow fell 56.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.83
0.03
+1.07%
Follow EVAX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 5 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | — | (16.65) | (16.30) | (4.54) |
P/S ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 2.84 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (38.52) | (36.69) | (10.33) |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | — | 37.74 | (2.17) |
P/Operating CF |
— | — | — | — | — | — | (19.45) | (0.52) | (3.93) |
P/B ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 1.78 |
Price to Tangible BV |
— | — | — | — | — | — | 0.00 | 0.00 | 1.79 |
EV/Sales |
— | — | — | — | — | — | 0.00 | 0.00 | 1.33 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (3.68) | (0.32) | (0.47) |
EV/FCF |
— | — | — | — | — | — | (3.61) | (0.32) | (0.47) |
Quick Ratio |
— | 0.87 | 6.03 | 1.56 | 7.76 | 3.77 | 0.90 | 1.72 | 5.66 |
Current Ratio |
— | 0.89 | 6.36 | 2.22 | 8.03 | 4.51 | 1.18 | 2.01 | 5.85 |
Net Debt/EBITDA |
— | (0.20) | 0.88 | 0.35 | 1.11 | 0.13 | (0.23) | (0.27) | 1.87 |
Debt/Assets |
0.00% | 101.82% | 0.32% | 0.17% | 8.41% | 45.19% | 81.81% | 78.39% | 25.15% |
Debt/Equity |
— | (9.31) | 0.00 | 0.00 | 0.10 | 1.20 | (2.23) | (5.92) | 0.42 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 0.37 |
Operating CF/Net income |
— | 0.36 | 0.63 | 0.83 | 0.89 | 1.11 | 0.80 | 1.22 | 0.86 |
Capex/Depreciation |
— | 0.00 | (0.75) | (1.75) | (3.96) | (0.51) | (0.14) | 0.00 | (0.02) |
Interest Coverage |
— | (777.62) | (8.89) | (74.30) | (28.23) | (16.75) | (13.20) | (4.72) | (2.31) |
| — | (131.17%) | (265.57%) | (183.15%) | (124.29%) | (113.74%) | (1,238.11%) | 331.20% | (100.18%) | |
| — | (129.91%) | (114.25%) | (130.31%) | (94.12%) | (74.51%) | (126.74%) | (83.29%) | (37.69%) | |
ROIC |
— | 0.00% | 0.00% | (846.00%) | (442.73%) | (311.38%) | (5,979.80%) | (421.78%) | (608.14%) |
Return on Tangible Assets |
— | 609.59% | (119.90%) | (240.52%) | (69.00%) | (129.45%) | (394.46%) | (133.57%) | (32.16%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,075.00 | 168.09 | 41.99 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16,323.29% | 312.71% | 132.51% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14,183.56% | 227.84% | 90.16% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 656.16% | 10.68% | 4.08% |
Graham Net Nets |
— | — | — | — | — | — | (0.09) | (1.75) | 0.45 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (35.97%) | (232.17%) | (43.42%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (29.03%) | (577.57%) | (100.88%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 3.12 | 1.17 |
Operating CF per Share |
— | (0.14) | (25.27) | (40.29) | (56.25) | (54.51) | (32.36) | (12.06) | (1.03) |
Capex per Share |
— | 0.00 | (0.22) | (0.60) | (3.49) | (0.62) | (0.16) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.14) | (25.49) | (40.89) | (59.74) | (55.13) | (32.52) | (12.06) | (1.04) |
Cash per Share |
— | 0.53 | 34.41 | 18.90 | 82.50 | 27.88 | 10.21 | 5.55 | 3.63 |
Shareholders Equity per Share |
— | (0.07) | 33.70 | 22.80 | 83.19 | 17.56 | (8.65) | (1.54) | 2.66 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.07) | 33.70 | 22.80 | 83.19 | 17.56 | (8.65) | (1.54) | 2.66 |
Free Cash Flow |
— | (1.98) | (7.08) | (12.62) | (23.29) | (26.07) | (17.78) | (12.94) | (6.64) |
Working Capital |
— | (1.04) | 9.24 | 6.02 | 30.38 | 13.22 | 1.27 | 4.40 | 20.64 |
Capital Expenditures |
— | (0.01) | (0.06) | (0.18) | (1.36) | (0.29) | (0.09) | — | (0.01) |
Net Current Asset Value |
— | (1.06) | 9.24 | 6.02 | 26.98 | 3.26 | (9.27) | (5.37) | 13.53 |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.19 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.57 | 0.80 | 0.48 | 0.07 | 0.12 | 0.14 | 0.17 | 0.19 |
Cash ROIC |
— | (13.03%) | (37.35%) | (97.91%) | (34.26%) | (82.91%) | (155.97%) | (91.86%) | (13.99%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 2.84 | 6.26 |
Accounts Payable Turnover |
— | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 1,659.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.85 | 0.80 | 1.33 | 1.62 | 1.21 | 0.91 | 1.18 | 1.20 |
Average Payables |
— | 0.79 | 0.49 | 2.16 | 3.26 | 2.47 | 2.39 | 2.83 | 2.58 |
Average Assets |
— | 4.26 | 9.80 | 11.52 | 26.06 | 31.09 | 17.46 | 12.69 | 20.45 |
Average Common Equity |
— | 4.22 | 4.22 | 8.20 | 19.74 | 20.37 | 1.79 | (3.19) | 7.69 |
Columns are period end dates